Somewhat Critical Press Coverage Somewhat Unlikely to Impact Novan (NOVN) Share Price

Headlines about Novan (NASDAQ:NOVN) have been trending somewhat negative this week, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novan earned a coverage optimism score of -0.05 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 42.9626436512867 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern’s rankings:

Novan (NOVN) opened at $4.38 on Monday. The firm has a market cap of $71.01 and a PE ratio of -2.04. Novan has a 1-year low of $3.52 and a 1-year high of $28.59.

NOVN has been the topic of a number of recent research reports. ValuEngine upgraded shares of Novan from a “strong sell” rating to a “sell” rating in a report on Friday, September 15th. Zacks Investment Research upgraded shares of Novan from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, Wedbush restated a “neutral” rating and issued a $6.00 target price on shares of Novan in a report on Monday, September 25th.

COPYRIGHT VIOLATION NOTICE: “Somewhat Critical Press Coverage Somewhat Unlikely to Impact Novan (NOVN) Share Price” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/25/somewhat-critical-press-coverage-somewhat-unlikely-to-impact-novan-novn-share-price.html.

About Novan

Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).

Insider Buying and Selling by Quarter for Novan (NASDAQ:NOVN)

Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit